Ror-gamma-t inhibitor, preparation method thereof and use thereof

A compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,

• wherein:
• R is C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C8 cycloalkylamino, —C1-6 alkylene-C3-8 cycloalkyl, C3-8 cycloalkyl, C1-6 haloalkyl or C1-6 haloalkoxy;
• each of Z1, Z2, Z3, Z4, Z5, Z6, Z7 and Z8 is independently CR1 or N;
• each R1 is independently hydrogen, deuterium, cyano, fluorine, chlorine, bromine, iodine, C1-6 alkyl, C1-6 haloalkyl, hydroxy-substituted C1-6 alkyl, —C1-6 alkylene-C1-6 alkoxy, C1-6 alkoxy, C8 cycloalkyl or 3- to 7-membered heterocyclyl;
• ring A is 3- to 5-membered heterocyclyl or 7-membered heterocyclyl, and each of the 3- to 5-membered heterocyclyl and 7-membered heterocyclyl is independently and optionally substituted with 1, 2, 3, 4 or 5 R2;
• wherein * represents the direction in which ring A is connected to ring C;
• each R2 is independently oxo, Ra, C1-6 alkyl, —C1-6 alkylene-Ra, —ORb, —C1-6 alkylene-ORb, —C(═O)—Ra, —C1-6 alkylene-C(═O)—Ra, —C(═O)—NRcRd or —C1-6 alkylene-C(═O)—NRcRd;
• each Ra is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, Cm cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclyl, 5- to 12-membered spirocyclyl, 4- to 12-membered fused cyclyl, 5- to 12-membered spiro heterocyclyl or 4- to 12-membered fused heterocyclyl;
• each Rb, Rc and Rd is independently hydrogen, deuterium, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C3-8 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclyl, 5- to 12-membered spirocyclyl, 4- to 12-membered fused cyclyl, 5- to 12-membered spiro heterocyclyl or 4- to 12-membered fused heterocyclyl;
• or, Rc and Rd together with the N atom to which they are attached form 4- to 7-membered heterocyclyl;
• wherein each Ra, Rb, Rc and Rd is independently and optionally substituted with 1, 2, 3, 4, 5 or 6 Rg;
• each Rg is independently deuterium, fluorine, chlorine, bromine, iodine, oxo, hydroxy, amino, nitro, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl or 3- to 7-membered heterocyclyl;
• ring B is C6-10 aryl, C3-8 cycloalkyl, 5- to 12-membered heteroaryl, 3- to 7-membered heterocyclyl, 4- to 12-membered fused heterocyclyl, 5- to 12-membered spiro heterocyclyl, 4- to 12-membered fused cyclyl or 5- to 12-membered spirocyclyl, wherein the ring B is optionally substituted with 1, 2, 3 or 4 Re;
• each Re is independently deuterium, fluorine, chlorine, bromine, iodine, cyano, nitro, hydroxy, amino, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, 3- to 7-membered heterocyclyl, C1-6 haloalkyl or C1-6 haloalkoxy, wherein each of the C1-6 alkyl, C1-6 alkoxy, Cm cycloalkyl, 3- to 7-membered heterocyclyl, C1-6 haloalkyl and C1-6 haloalkoxy is independently and optionally substituted with 1, 2, 3 or 4 substituents selected from cyano, nitro, hydroxy, amino or 3- to 7-membered heterocyclyl;
• L1 is —S(═O)2—NH—, —NH—S(═O)2—, —S(═O)—NH—, —NH—S(═O)—, —C(═O)NH— or —NHC(═O)—;
• L2 is a bond or —CR3R4—;
• L3 is —C(═O)—, —S—, —O—, —NR5— or —CR6R′—;
• R3 is hydrogen, deuterium, hydroxy-substituted C1-6 alkyl, —C1-6 alkylene-OC(═O)—Rf, —C1-6 alkylene-C(═O)—O—Rf or —C1-6 alkylene-Rf;
• Rf is C2-6 alkyl, amino-substituted C1-6 alkyl, C1-6 haloalkyl, —C1-6 alkylene-C(═O)—OR6 or —OP(═O)—(ORm)(ORm);
• wherein each of Rh, Rm and Rn is independently hydrogen, deuterium, sodium, potassium, C1-6 alkyl or C1-6 haloalkyl;
• R4 is hydrogen, deuterium or hydroxy-substituted C1-6 alkyl;
• R5 is hydrogen, deuterium, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C3 cycloalkyl or 3- to 6-membered heterocyclyl;
• each of R6 and R7 is independently hydrogen, deuterium, C1-4 alkyl, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 alkoxy, C3 cycloalkyl or 3- to 6-membered heterocyclyl.